TY - JOUR
T1 - High-risk human papillomavirus genotype distribution among women living with and at risk for HIV in Africa
AU - Chachage, Mkunde
AU - Parikh, Ajay P.
AU - Mahenge, Anifrid
AU - Bahemana, Emmanuel
AU - Mnkai, Jonathan
AU - Mbuya, Wilbert
AU - Mcharo, Ruby
AU - Maganga, Lucas
AU - Mwamwaja, Jaqueline
AU - Gervas, Reginald
AU - Kibuuka, Hannah
AU - Maswai, Jonah
AU - Singoei, Valentine
AU - Iroezindu, Michael
AU - Fasina, Abiola
AU - Esber, Allahna
AU - Dear, Nicole
AU - Imbach, Michelle
AU - Crowell, Trevor A.
AU - Hern, Jaclyn
AU - Song, Xiaofang
AU - Hoelscher, Michael
AU - Polyak, Christina S.
AU - Ake, Julie A.
AU - Geldmacher, Christof
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/3/15
Y1 - 2023/3/15
N2 - Objective:Cervical cancer is a common preventable cancer among African women living with HIV (WLWH). Molecular diagnostics for high-risk human papillomavirus (HR-HPV) genotypes are standard components of cervical cancer screening in resource-rich countries but not in resource-limited settings. We evaluated HR-HPV genotypes among women with and without HIV in four African countries to inform cervical cancer preventive strategies.Methods:The African Cohort Study (AFRICOS) enrolled participants with and without HIV at 12 clinics in Tanzania, Kenya, Uganda, and Nigeria. Cervical cytobrush specimens from women were genotyped for 14 HR-HPV types using the multiplex Seegene Anyplex real-time PCR assay. Robust Poisson regression was used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for factors associated with HR-HPV in WLWH.Results:From January 2015 to March 2020, 868 WLWH and 134 women living without HIV (WLWoH) were tested for HR-HPV with prevalence of 50.9 and 38.1%, respectively (P = 0.007). Among WLWH, 844 (97.4%) were antiretroviral therapy (ART)-experienced and 772 (89.7%) virally suppressed 1000 copies/ml or less. The most frequent HR-HPV types among WLWH were HPV-16 (13.5%), HPV-52 (9.5%), and HPV-35 (9.3%). HR-HPV infection was more common among Tanzanian WLWH (adjusted RR: 1.23, 95% CI 1.05-1.44, P = 0.012). Also, WLWH with CD4+T cells of less than 200 cell/μl had 1.51-fold increased risk of having HR-HPV (95% CI 1.23-1.86, P < 0.001).Conclusion:HR-HPV was common in WLWH in four African countries, particularly among women with low CD4+cell count. Scale up of HPV vaccines and development of vaccines with broader activity against less common HR-HPV types may improve cervical cancer prevention in Africa.
AB - Objective:Cervical cancer is a common preventable cancer among African women living with HIV (WLWH). Molecular diagnostics for high-risk human papillomavirus (HR-HPV) genotypes are standard components of cervical cancer screening in resource-rich countries but not in resource-limited settings. We evaluated HR-HPV genotypes among women with and without HIV in four African countries to inform cervical cancer preventive strategies.Methods:The African Cohort Study (AFRICOS) enrolled participants with and without HIV at 12 clinics in Tanzania, Kenya, Uganda, and Nigeria. Cervical cytobrush specimens from women were genotyped for 14 HR-HPV types using the multiplex Seegene Anyplex real-time PCR assay. Robust Poisson regression was used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for factors associated with HR-HPV in WLWH.Results:From January 2015 to March 2020, 868 WLWH and 134 women living without HIV (WLWoH) were tested for HR-HPV with prevalence of 50.9 and 38.1%, respectively (P = 0.007). Among WLWH, 844 (97.4%) were antiretroviral therapy (ART)-experienced and 772 (89.7%) virally suppressed 1000 copies/ml or less. The most frequent HR-HPV types among WLWH were HPV-16 (13.5%), HPV-52 (9.5%), and HPV-35 (9.3%). HR-HPV infection was more common among Tanzanian WLWH (adjusted RR: 1.23, 95% CI 1.05-1.44, P = 0.012). Also, WLWH with CD4+T cells of less than 200 cell/μl had 1.51-fold increased risk of having HR-HPV (95% CI 1.23-1.86, P < 0.001).Conclusion:HR-HPV was common in WLWH in four African countries, particularly among women with low CD4+cell count. Scale up of HPV vaccines and development of vaccines with broader activity against less common HR-HPV types may improve cervical cancer prevention in Africa.
KW - AIDS
KW - Africa
KW - HIV
KW - antiretroviral therapy
KW - high-risk human papilloma virus
KW - uterine cervical neoplasms
KW - women living with HIV
UR - http://www.scopus.com/inward/record.url?scp=85148678916&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000003437
DO - 10.1097/QAD.0000000000003437
M3 - Article
C2 - 36398743
AN - SCOPUS:85148678916
SN - 0269-9370
VL - 37
SP - 625
EP - 635
JO - AIDS
JF - AIDS
IS - 4
ER -